《新股消息》微創醫療(00853.HK)分拆微創腦科學通過聯交所上市聆訊
微創醫療(00853.HK)公布,旗下分拆的微創腦科學已通過香港聯交所上市聆訊。摩通及中金為聯席保薦人。
微創腦科學為內地神經介入醫療器械公司,產品組合累積共有30款,包括在中國獲得批准並商業化的10款治療產品及3款通路產品,以及17款正在開發的候選產品。獲批准的治療產品組合,涵蓋神經血管疾病的三大領域,即出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中。
公司截至2021年12月底止,收入約3.83億元人民幣(下同),按年升72.5%;純利則按年跌46.6%至2,417萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.